Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.
about
Glucagon secretion and signaling in the development of diabetesManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Short acting insulin analogues versus regular human insulin in patients with diabetes mellitusShort acting insulin analogues versus regular human insulin in patients with diabetes mellitusStandards of medical care in diabetes--2012Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesTreating type 1 diabetes: from strategies for insulin delivery to dual hormonal controlCausative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetesPatient safety and minimizing risk with insulin administration - role of insulin degludecOptimal management of type 2 diabetes in patients with increased risk of hypoglycemiaRecommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profileStandards of medical care in diabetes--2013The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis.Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.Hypoglycemia Reduction and Accuracy of Continuous Glucose MonitoringCognitive, behavioural and psychological barriers to the prevention of severe hypoglycaemia: A qualitative study of adults with type 1 diabetes.New insights into seaweed polyphenols on glucose homeostasis.Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetesDiabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes.Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyAssociation of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetesModels of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.Hypoglycemia prevention via pump attenuation and red-yellow-green "traffic" lights using continuous glucose monitoring and insulin pump dataImpact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study.Pancreatic network control of glucagon secretion and counterregulation.Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.Control to range for diabetes: functionality and modular architecture.System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.Physical activity into the meal glucose-insulin model of type 1 diabetes: in silico studies.Physical activity-the major unaccounted impediment to closed loop control.Hypoglycemia detection and prediction using continuous glucose monitoring-a study on hypoglycemic clamp dataThe median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus.Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated ratsA model of self-treatment behavior, glucose variability, and hypoglycemia-associated autonomic failure in type 1 diabetes.Assessment and management of hypoglycemia in children and adolescents with diabetes.Evaluation of an Algorithm for Retrospective Hypoglycemia Detection Using Professional Continuous Glucose Monitoring Data.A comparison of different statistical methods analyzing hypoglycemia data using bootstrap simulations.Localized in vivo 13C NMR spectroscopy of the brainCerebral glutamate metabolism during hypoglycaemia in healthy and type 1 diabetic humans.
P2860
Q21129250-805DE8AF-EB67-4958-9CED-0ED5FB2745B0Q22241288-41C010C7-2F2E-4FE7-9AD8-EAE3C82CF2BDQ24246142-A7BD2BA9-499B-417E-8819-DD2D4C39D962Q24246326-8265F9E5-1859-406B-8E97-0551DA4EC26FQ24632533-79607F4F-ABA6-4B0D-9616-B0DD3BDD9E94Q26827955-2E904DDF-67C8-44D0-B0EB-59F2BE59A4DFQ26853250-9C26FE94-06F5-414C-80DD-E85220EFEBE4Q27008460-6DB0AFCC-2556-449B-8805-D3C69BCE34A9Q27025548-99C4C93D-4942-42F2-813A-82179E2855A1Q27026847-899F0405-988E-4DF3-BE5C-36CE0B95E134Q27687563-4037DD68-9615-4DB3-8BF2-A900A0AD7C54Q29620309-DD498601-1800-41F1-AF83-AAA1B0DB3BBDQ30238675-CCE9D390-7972-4497-978A-01E5FAAD7FD9Q30252932-276E121E-11C5-4249-A069-FDC72F19DA6EQ30276764-94D2C25B-CAD5-4376-965A-97137C597952Q30299941-60DEF591-0896-4490-9F17-5923D728AC92Q30361562-5245E53A-23E2-4891-876E-DD902DB6F6B6Q30371177-B098686C-0BB0-47F4-BF4F-9583EA4EF9C3Q30371583-EB18EA87-5C04-43F5-BAB0-F23A0B7B1543Q30416241-444812C6-0625-4B7F-B0AC-B4C6F5825B12Q30424699-DA5C9EAE-1843-4EE9-AD89-16FD285EDEA6Q30427914-38EE5C2B-6DB1-4636-B0CF-A95C591D5438Q30429992-4C677675-A675-4BF0-8529-CC814C54A323Q30430888-60BD5D9D-D5C0-4910-9CD4-1F8FF093B95EQ30432525-03D76AC1-7686-4857-B475-B3A23D824616Q30432736-C66CCDAD-8D1E-417A-AE4D-728235C01AA2Q30434101-53238EFD-9C77-44F9-BF4E-C0711A10CC15Q30434937-3F191F54-4945-4755-99F1-624FF7D0CC6BQ30437499-629B711A-53A1-4C7B-A32D-0C8FD45CEEE8Q30437503-0D52BFB4-78AE-4DBE-94D3-270CFE20E2C3Q30437987-141867F2-5AA3-4668-9A42-5464D2235969Q30438000-04AF628D-6019-4BE2-90A2-E7D58207A880Q30438605-35DF01C4-E505-461B-9D3F-9E685234B245Q30438739-2809C022-DD69-4CD5-9C6B-A4EFCEBD9223Q30439212-6100BF9E-C559-4AF3-9528-7E70D2AFD293Q30445990-D3FBD618-9B9A-42AF-927B-B361ED8E42F4Q30827665-99E79A31-6DF4-4980-8DDF-6DBF1A9B3568Q30829473-1BD6A34D-DACA-481E-BC2A-E46A0739FA9BQ30886268-714AD20E-180E-43C7-A5B0-BC830DF41EE8Q31033177-4876E915-1A37-429A-AE4E-BD9881709668
P2860
Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@ast
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@en
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@nl
type
label
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@ast
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@en
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@nl
prefLabel
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@ast
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@en
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@nl
P921
P1433
P1476
Hypoglycaemia: the limiting fa ...... f Type I and Type II diabetes.
@en
P2093
P2888
P304
P356
10.1007/S00125-002-0822-9
P577
2002-04-26T00:00:00Z
P5875
P6179
1039450592